

Supplementart Materials

DLK1	AECFPACNPQNGFCEDDNVCRCHVGWQGGLCDQCVTSPGCLHLGCGEPGQCICITDGDWDELCDRDVACSSAPC ANNGTCVSLDGGLYECSCAPGYSGKDCQKKDGPCVINGSPCQHGGTCVDDEGRASHASCLCPPGFSGNFCEIVANS CTPNPCENDGVCTDIGGDFRCRCPAGFIDKTCRPVTNCASSPCQNGGTCLQHTQVSYECLCKPEFTGLTCVKKRAL SPQQVTRLPSGYGLAYRLTPGVHELVPVQQPEHRILKVSMEKLNKKTPLLTEGQ
Fc	EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPR EEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHYTQKSLSLSPGK
VH	EB3 EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKLEWWSAISGSGGSTYYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAKSYRVFDYWGQGLTVVSS
VL	EB3 SSELTDQPAVSVALGQTVRITCQGDSLSRYYSWYQQKPGQAPVLIYGKNNRPSGIPDRFSGSSSGNTASLTITGAQAEADYYCNSSDPWPKVVFVGGGKLTVLG

Figure S1. Aminoacid sequence of the scFv(EB3).




Figure S2. (A) BIAcore profile of SIP(EB3) against the extra domain A of fibronectin coated on the CM5 chip demonstrates absence of binding. (B) BIAcore profiles of SIP(EB3), SIP(F8) and SIP(KSF) antibodies against DLK1-Fc fusion protein coated on the CM5 chip, respectively.




Figure S3. Radioiodinated preparation of SIP(EB3) was injected into nude mice, bearing subcutaneously-grafted U87 tumors. Twentyfour hours after intravenous administration, SIP(EB3) failed to localize to the neoplastic lesions *in vivo*.